Treg Hypothesis Validated in Inflammatory Skin Diseases: Rezpegaldesleukin Shows Promise in AD, PsO
Rezpegaldesleukin showed durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes in patients with atopic dermatitis (AD) and psoriasis (PsO), according to two Phase 1b studies in Nature Communications. Under development as a self-administered injection, rezpegaldesleukin is a first-in-class interleukin-2 receptor (IL-2R) agonist that enhances the activity of regulatory T cells (Tregs). It is wholly-owned by Nektar Therapeutics. […]